Know Cancer

forgot password

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/Phase 2
2 Years
18 Years
Open (Enrolling)
Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma

Thank you

Trial Information

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Inclusion Criteria:

- Male or female patients aged 2 to <18 years (5 to <18 years for Hodgkin lymphoma

- Diagnosis of systemic anaplastic large-cell lymphoma, or Hodgkin lymphoma for which
standard, curative, life-prolonging, or palliative treatment does not exist or is no
longer effective

- Patients with systemic anaplastic large-cell lymphoma (sALCL) must have documented
anaplastic lymphoma kinase (ALK) status and must be beyond first remission or
refractory to front-line chemotherapy

- Patients diagnosed with any relapsed or refractory CD30+ hematologic malignancy
(e.g., primary mediastinal B-cell lymphoma) may be included in phase 1 of the study

- Patients with HL must be in their second of later relapse, have failed systemic
chemotherapy either as induction therapy for advanced stage disease or salvage
therapy, and were ineligible for, refused, or previously received a stem cell

- Performance score ≥ 60 from Lansky Play Performance Scale if < 16 years

- Negative pregnancy test

- Fertile patients must use effective contraception prior to and through 6 months after
the last dose of the study drug

Exclusion Criteria:

- Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible)

- Received an allogeneic stem cell transplant <6 months prior to the first dose of
study medication, or presence of polymerase chain reaction (PCR)-detectable
cytomegalovirus (CMV) in any post-allogeneic transplant patient

- Receiving immunosuppressive therapy

- Receiving systemic therapy for chronic graft-versus-host disease (topical therapy is

- Previous treatment with any anti-CD30 antibody

- Therapeutic monoclonal antibody use within the longer of 6 weeks or 5 plasma

- Systemic cardiac disease that would, in the opinion of the investigator or medical
monitor, interfere with assessment of efficacy or safety of the drug

- History of another primary malignancy not in remission for at least 3 years (the
following are exempt from the 3-year limit: nonmelanoma skin cancer and cervical
carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)

- Known active cerebral/meningeal disease, including signs or symptoms of progressive
multifocal leukoencephalopathy (PML)

- History of cirrhosis

- Active systemic viral, bacterial, or fungal infection requiring antimicrobial,
antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of
study drug (routine antimicrobial prophylaxis is acceptable)

- Concurrent therapy with other anti-neoplastic or experimental agents

- Systemic corticosteroid therapy <14 days prior to first dose of the study medication

- Any serious underlying medical condition that, in the opinion of the investigator or
medical monitor, would impair their ability to receive or tolerate the planned

- Known hypersensitivity to recombinant proteins, murine proteins, or any excipient
contained in the drug formulation

- Received nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to
the first study dose

- Prior autologous hematopoietic stem cell infusion <6 weeks prior to first study dose

- Grade 2 or greater unresolved toxicity from prior antineoplastic therapy

- Grade 2 or greater peripheral neuropathy

- Female patients who are both lactating and breastfeeding, or have a positive serum
pregnancy test during the screening period or a positive urine pregnancy test on Day
1 before the first dose of study drug

- Received local palliative radiation therapy <14 days prior to the first dose of study

- Received radiation therapy to more than 25% of the bone marrow-containing spaces < 84
days prior to first dose of study medication

- Received a strong inhibitor of CYP3A4 <2 weeks prior to first study dose

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Adverse events, serious adverse events, assessments of clinical and laboratory values, and vital sign measurements (phase 1)

Outcome Description:

To assess the safety profile and determine the pediatric maximum tolerated dose and/or recommended phase 2 dose of brentuximab vedotin

Outcome Time Frame:

From the time informed consent is signed through 30 days after the last dose of study drug, approximately 12 months

Safety Issue:


Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Millennium Pharmaceuticals, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

December 2011

Completion Date:

April 2016

Related Keywords:

  • Hodgkin Lymphoma
  • Anaplastic Large-Cell Lymphoma
  • Pediatric
  • Lymphoma
  • Hodgkin
  • Anaplastic Large-cell
  • Relapsed
  • Refractory
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic



Children's Mercy Hospital Kansas City, Missouri  64108
Memorial Sloan - Kettering Cancer Center New York, New York  10021
The University of Texas, MD Anderson Cancer Center Houston, Texas  77030
Children's Hospital Colorado Aurora, Colorado  80045